Metastatic Renal Cell Cancer Treated With Antiangiogenic Therapy Monitoring by 18F-FDG PET/CT.

Renal cell carcinoma (RCC) is resistant to chemotherapy and radiotherapy in most cases, and surgery is the preferred option in patients with local tough advanced disease. Even in metastatic RCC, patient survival has been reported to improve after surgery. Considering the importance of angiogenesis in RCC pathogenesis, new inhibitors of vascular endothelial growth factor pathway show promising results.

Therapeutic Algorithm Guided by Sequential 11C-Choline PET/CT in a Patient With Metastatic Castration-Resistant Prostate Cancer.

Antiandrogen therapy alone or combined with radical therapy is the first choice in diagnosis and recurrence of patients with metastatic prostate cancer. However, patients on androgen deprivation frequently show treatment resistance. In recent years, new treatments for metastatic castration-resistant prostate cancer have been developed.

Dual-phase 11C-choline PET/computed tomography in the early evaluation of prostate cancer recurrence.

Purpose: The aim of this study was to assess dual-phase 11C-choline PET/computed tomography (CT) for differentiating benign from malignant lesions in patients with biochemical recurrence of prostate cancer.

Materials And Methods: We prospectively studied 56 patients with prostate cancer treated by surgery (n=22) or radiotherapy (n=34) who had hypermetabolic foci on 11C-choline PET/CT determined for biochemical recurrence (prostate-specific antigen 1.23-9.

Incidental diagnosis of diffuse large B-cell lymphoma by 11C-choline PET/CT in a patient with biochemical recurrence of prostate cancer.

The main indication for C-choline PET/CT in prostate cancer patients is the early localization of biochemical recurrence after radical treatment. However, any C-choline uptake should be assessed in terms of physiological distribution and patterns of tumor spread. Therefore, tracer-avid lesions in unexpected sites should be carefully addressed because the diagnosis of other malignancies has important therapeutic implications.

Influence of subcutaneous administration of rapid-acting insulin in the quality of (18)F-FDG PET/CT studies.

Objective: The aim of this study was to develop a protocol for normalizing blood glucose levels in diabetic patients by subcutaneously administering rapid-acting insulin before administering (18)F-fluorodeoxyglucose ((18)F-FDG) without hindering the quality of PET/computed tomography (CT) studies.

Materials And Methods: The study included 120 patients, who were divided into four groups: Group I: This group comprised 30 diabetic patients with blood glucose levels lower than 160 mg/dl at the time of arrival at our center; in these patients, (18)F-FDG was injected without prior administration of subcutaneous rapid-acting insulin. Group II: This group comprised 30 diabetic patients with blood glucose levels ranging from 168 to 260 mg/dl; in these patients, subcutaneous rapid-acting insulin was administered and then (18)F-FDG was injected when blood glucose levels dropped below 160 mg/dl (30-115 min).

Bone metastases from prostate cancer: 18F-fluoride PET/CT in a patient with discordant bone scintigraphy and 11C-choline PET/CT.

Bone scintigraphy has been used extensively in prostate cancer patients to detect bone involvement. (11)C-choline PET/CT is indicated when a biochemical recurrence is suspected, as this procedure is able to detect local recurrence, lymph-node infiltration, and metastases.In cases where the results of these 2 procedures do not coincide, MRI is then usually performed.